Copyright Reports & Markets. All rights reserved.

Global Breast Cancer Therapeutics Drugs Market Insights, Forecast to 2025

Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Breast Cancer Therapeutics Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Breast Cancer Therapeutics Drugs Market Size Growth Rate by Product
      • 1.4.2 Mitotic Inhibitors
      • 1.4.3 Anti-Metabolites
      • 1.4.4 Hormone Receptor
      • 1.4.5 Aromatase Inhibitors
      • 1.4.6 HER2 Inhibitors
    • 1.5 Market by End User
      • 1.5.1 Global Breast Cancer Therapeutics Drugs Market Size Growth Rate by End User
      • 1.5.2 Phase I
      • 1.5.3 Phase II
      • 1.5.4 Phase III
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Breast Cancer Therapeutics Drugs Market Size
      • 2.1.1 Global Breast Cancer Therapeutics Drugs Revenue 2014-2025
      • 2.1.2 Global Breast Cancer Therapeutics Drugs Sales 2014-2025
    • 2.2 Breast Cancer Therapeutics Drugs Growth Rate by Regions
      • 2.2.1 Global Breast Cancer Therapeutics Drugs Sales by Regions
      • 2.2.2 Global Breast Cancer Therapeutics Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Breast Cancer Therapeutics Drugs Sales by Manufacturers
      • 3.1.1 Breast Cancer Therapeutics Drugs Sales by Manufacturers
      • 3.1.2 Breast Cancer Therapeutics Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Breast Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Breast Cancer Therapeutics Drugs Revenue by Manufacturers
      • 3.2.1 Breast Cancer Therapeutics Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Breast Cancer Therapeutics Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Breast Cancer Therapeutics Drugs Price by Manufacturers
    • 3.4 Breast Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Breast Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Breast Cancer Therapeutics Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Breast Cancer Therapeutics Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Breast Cancer Therapeutics Drugs Sales by Product
    • 4.2 Global Breast Cancer Therapeutics Drugs Revenue by Product
    • 4.3 Breast Cancer Therapeutics Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Breast Cancer Therapeutics Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Breast Cancer Therapeutics Drugs by Countries
      • 6.1.1 North America Breast Cancer Therapeutics Drugs Sales by Countries
      • 6.1.2 North America Breast Cancer Therapeutics Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Breast Cancer Therapeutics Drugs by Product
    • 6.3 North America Breast Cancer Therapeutics Drugs by End User

    7 Europe

    • 7.1 Europe Breast Cancer Therapeutics Drugs by Countries
      • 7.1.1 Europe Breast Cancer Therapeutics Drugs Sales by Countries
      • 7.1.2 Europe Breast Cancer Therapeutics Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Breast Cancer Therapeutics Drugs by Product
    • 7.3 Europe Breast Cancer Therapeutics Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Breast Cancer Therapeutics Drugs by Countries
      • 8.1.1 Asia Pacific Breast Cancer Therapeutics Drugs Sales by Countries
      • 8.1.2 Asia Pacific Breast Cancer Therapeutics Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Breast Cancer Therapeutics Drugs by Product
    • 8.3 Asia Pacific Breast Cancer Therapeutics Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Breast Cancer Therapeutics Drugs by Countries
      • 9.1.1 Central & South America Breast Cancer Therapeutics Drugs Sales by Countries
      • 9.1.2 Central & South America Breast Cancer Therapeutics Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Breast Cancer Therapeutics Drugs by Product
    • 9.3 Central & South America Breast Cancer Therapeutics Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Breast Cancer Therapeutics Drugs by Countries
      • 10.1.1 Middle East and Africa Breast Cancer Therapeutics Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Breast Cancer Therapeutics Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Breast Cancer Therapeutics Drugs by Product
    • 10.3 Middle East and Africa Breast Cancer Therapeutics Drugs by End User

    11 Company Profiles

    • 11.1 Bayer HealthCare
      • 11.1.1 Bayer HealthCare Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Bayer HealthCare Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Bayer HealthCare Breast Cancer Therapeutics Drugs Products Offered
      • 11.1.5 Bayer HealthCare Recent Development
    • 11.2 Eli Lily
      • 11.2.1 Eli Lily Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Eli Lily Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Eli Lily Breast Cancer Therapeutics Drugs Products Offered
      • 11.2.5 Eli Lily Recent Development
    • 11.3 Pfizer
      • 11.3.1 Pfizer Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Pfizer Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Pfizer Breast Cancer Therapeutics Drugs Products Offered
      • 11.3.5 Pfizer Recent Development
    • 11.4 Novartis
      • 11.4.1 Novartis Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Novartis Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Novartis Breast Cancer Therapeutics Drugs Products Offered
      • 11.4.5 Novartis Recent Development
    • 11.5 Eisai
      • 11.5.1 Eisai Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eisai Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eisai Breast Cancer Therapeutics Drugs Products Offered
      • 11.5.5 Eisai Recent Development
    • 11.6 Halozyme Therapeutics
      • 11.6.1 Halozyme Therapeutics Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Halozyme Therapeutics Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Halozyme Therapeutics Breast Cancer Therapeutics Drugs Products Offered
      • 11.6.5 Halozyme Therapeutics Recent Development
    • 11.7 Roche
      • 11.7.1 Roche Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Roche Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Roche Breast Cancer Therapeutics Drugs Products Offered
      • 11.7.5 Roche Recent Development
    • 11.8 Puma Biotechnology
      • 11.8.1 Puma Biotechnology Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Puma Biotechnology Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Puma Biotechnology Breast Cancer Therapeutics Drugs Products Offered
      • 11.8.5 Puma Biotechnology Recent Development
    • 11.9 Janssen Biotech
      • 11.9.1 Janssen Biotech Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Janssen Biotech Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Janssen Biotech Breast Cancer Therapeutics Drugs Products Offered
      • 11.9.5 Janssen Biotech Recent Development
    • 11.10 AbbVie
      • 11.10.1 AbbVie Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 AbbVie Breast Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 AbbVie Breast Cancer Therapeutics Drugs Products Offered
      • 11.10.5 AbbVie Recent Development
    • 11.11 BioMarin
    • 11.12 Array BioPharma
    • 11.13 Merck
    • 11.14 Syndax
    • 11.15 MacroGenics
    • 11.16 ImmunoGen
    • 11.17 Santen Pharma
    • 11.18 Celgene
    • 11.19 Oncothyreon
    • 11.20 AstraZeneca
    • 11.21 Sprint Bioscience
    • 11.22 Genentech
    • 11.23 Galena Biopharma
    • 11.24 Lycera
    • 11.25 CTI BioPharma

    12 Future Forecast

    • 12.1 Breast Cancer Therapeutics Drugs Market Forecast by Regions
      • 12.1.1 Global Breast Cancer Therapeutics Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Breast Cancer Therapeutics Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Breast Cancer Therapeutics Drugs Market Forecast by Product
      • 12.2.1 Global Breast Cancer Therapeutics Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Breast Cancer Therapeutics Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Breast Cancer Therapeutics Drugs Market Forecast by End User
    • 12.4 North America Breast Cancer Therapeutics Drugs Forecast
    • 12.5 Europe Breast Cancer Therapeutics Drugs Forecast
    • 12.6 Asia Pacific Breast Cancer Therapeutics Drugs Forecast
    • 12.7 Central & South America Breast Cancer Therapeutics Drugs Forecast
    • 12.8 Middle East and Africa Breast Cancer Therapeutics Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Breast Cancer Therapeutics Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Breast Cancer Therapeutics Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Breast Cancer Therapeutics Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Breast Cancer Therapeutics Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Breast Cancer Therapeutics Drugs in these regions.
      This research report categorizes the global Breast Cancer Therapeutics Drugs market by top players/brands, region, type and end user. This report also studies the global Breast Cancer Therapeutics Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Bayer HealthCare
      Eli Lily
      Pfizer
      Novartis
      Eisai
      Halozyme Therapeutics
      Roche
      Puma Biotechnology
      Janssen Biotech
      AbbVie
      BioMarin
      Array BioPharma
      Merck
      Syndax
      MacroGenics
      ImmunoGen
      Santen Pharma
      Celgene
      Oncothyreon
      AstraZeneca
      Sprint Bioscience
      Genentech
      Galena Biopharma
      Lycera
      CTI BioPharma

      Market size by Product
      Mitotic Inhibitors
      Anti-Metabolites
      Hormone Receptor
      Aromatase Inhibitors
      HER2 Inhibitors
      Market size by End User
      Phase I
      Phase II
      Phase III

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Breast Cancer Therapeutics Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Breast Cancer Therapeutics Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Breast Cancer Therapeutics Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Breast Cancer Therapeutics Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Breast Cancer Therapeutics Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Breast Cancer Therapeutics Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now